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This thesis describes the translational genomics of HIV-1subtype C in India from its 
origin to therapeutic response with the aim to improve our knowledge for better 
therapeutic and preventive strategies to combat HIV/AIDS. In a systemic approach, we 
identified the molecular phylogeny of HIV-1 subtypes circulating in India and the time 
to most recent common ancestors (tMRCA) of predominant HIV-1 subtype C strains. 
Additionally, this thesis also studied drug resistance mutations in children, adolescents 
and adults, the role of host factors in evolution of drug resistance, and population 
dynamics of viremia and viral co-receptor tropism in perinatal transmission. Finally, 
the long term therapeutic responses on Indian national first-line antiretroviral therapy 
were also studied.  
In Paper I, we reported an increase in the HIV-1 recombinant forms in the HIV-1 
epidemiology using a robust subtyping methodology. While the study confirmed HIV-
1 subtype C as a dominant subtype, its origin was dated back to the early 1970s from a 
single or few genetically related strains from South Africa, whereafter, it has evolved 
independently. In Paper II, the lethal hypermutations due to the activity of human 
apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (hA3G) was 
significantly associated with antiretroviral therapy (ART) failure in Indian HIV-1 
subtype C patients. The presence of M184I and M230I mutations were observed due to 
the editing of hA3G in the proviral compartment but stop codons were also found in 
the open reading frames and the same drug resistance mutations were absent in plasma 
virus. Therefore, it is unlikely that the viral variants which exhibit hypermutated 
sequences and M184I and/or M230I will mature and expand in vivo and hence are 
unlikely to have any clinical significance. The high concordance of drug resistance 
genotyping in the plasma and proviral compartments in therapy-naïve patients, gives 
weight to the idea of using whole blood for surveillance of drug resistance mutations 
which precludes logistic challenges of cold chain transport.  
In Papers III and IV, we identified a substantial proportion of HIV-1 subtype C 
perinatally-infected older children who had a high burden of plasma viremia but also 
had high CD4
+ 
T-cell counts. In addition, older children with HIV-1 subtype C 
infection presented a high prevalence of predicted X4 and R5/X4 tropic strains which 
indicates that HIV-1 subtype C strains required longer duration of infection and 
greater disease progression to co-receptor transition from R5- to X4-tropic strains 
(IV). Our studies also indicate that transmitted drug resistance is low among Indian 
HIV-1 infected children, adolescents (III) and adults (II).  
In Paper V, in a longitudinal cohort study, a good long-term response to the Indian 
national first-line therapy for a median of nearly four years with 2.8% viral failure, 
indicating the overall success of the Indian ART program. Our study also showed that 
three immunologically well patients with virological rebound and major viral drug 
resistance mutations (M184V, K103N and Y181C) during one study visit had 
undetectable viral load at their next visit. These findings suggest that use of multiple 
parameters like patients’ immunological (CD4+ T-cell count), virological (viral load) 
and drug resistance data should all be used to optimize the treatment switch to second 
line therapy.  
In conclusion, this translational genomics study enhances our knowledge about the 
HIV-1 subtype C strains circulating in India which are genetically distinct from 
prototype African subtype C strains. Considerably more research using appropriate 
models need to be performed to understand the phenotypic and biological 
characteristics of these strains to guide efficient disease intervention and management 
strategies.   
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1 INTRODUCTION 
1.1 THE GLOBAL HIV-1 PANDEMIC 
The Human Immunodeficiency Virus type 1 (HIV-1)-induced acquired 
immunodeficiency syndrome (AIDS) pandemic, has emerged as a major medical and 
public health concern for the past three decades ever since the isolation of the virus in 
early 1980s [1-4]. As per the 2012 Joint United Nations programme on HIV/AIDS 
(UNAIDS) report, it is estimated that globally there are 34 million people living with 
HIV/AIDS (PLHA) at the end of 2011 [5] across almost all the parts of the world (Fig. 
1). Sub Saharan Africa continues to harbor  the highest burden of PLHA, which 
accounts for nearly 67% of the global infections [6] followed by India  with 2.4 million 
PLHA [7]. However, wide access to antiretroviral therapy (ART) has resulted in an 
encouraging decline in the incidence of the number of new annual HIV infections and 




Figure 1. Global prevalence of HIV, 2009 [Source: UNAIDS] 
 
1.1.1 HIV/AIDS EPIDEMIC IN INDIA 
India is the second most populated country in the world comprising of more than one 
billion people that accounts for 17% of the global population (WHO Country Profile) 
distributed across 28 states and 7 union territories with a total land area of 
1,269,219 sq miles. The first case of HIV in India was reported in 1986 among 
commercial sex workers in Chennai, Tamil Nadu, southern part of India [8]. Since then, 
it has spread to almost all parts of the country with an estimate of 2.4 million infections 
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as of 2009 and a prevalence of 0.31% of the general population [7]. Despite the low 
prevalence, demographically, India has become the third largest country with people 
living with HIV/AIDS after South Africa and Nigeria [7]. 
The epidemic is mainly restricted to high risk groups such as Female Sex Workers 
(FSW), Injecting Drug Users 
(IDU) and Men who have Sex with 
Men (MSM) including 
transgenders. The predominant 
mode of transmission is 
heterosexual (87.4%), followed by 
mother to child transmissions 
(5.4%). However, in certain regions 
of the country, the prevalence of 
HIV-infections in the IDUs and 
MSMs are noteworthy. Due to this 
heterogeneous spread of the 
epidemic, some geographical 
pockets have shown high incidence 
of HIV/AIDS (Fig. 2).  As per 
2009 estimates, the highest 
estimated adult HIV prevalence was in Manipur (1.40%), followed by Andhra 
Pradesh (0.90%), Mizoram (0.81%), Nagaland (0.78%), Karnataka (0.63%) and 
Maharashtra (0.55%). 
Following the identification of HIV/AIDS cases, the Ministry of Health and Family 
Welfare, Government of India (GoI), initiated prevention and awareness programmes 
on HIV/AIDS through the Medium Term Plan (1990-92). This has been further 
extended to the National AIDS Control Programme (NACP) by three strategic phases 
[NACP-I (1992-99), NACP-II (1999-2006) and NACP-III (2006-2011)]. Targeted 
interventions among the high risk groups, executed with the assistance of various 
nodal non-governmental organisations and community-based organisations have 
shown promising results with a decline in prevalence of PHLA from 0.39% in 2004 
to 0.31% in 2009. Owing to the encouraging results from the previous NACP 
program, the GoI has initiated the NACP-IV program which is currently in the 
planning phase.  
Figure 2.  State wise adult HIV-1 prevalence in India 
(2009 estimates). Data adapted from National AIDS 
Control Programme Phase III, State Fact Sheets, March 
2012. 
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1.2 THE ORIGIN AND CLASSIFICATION OF HIV   
Current scientific evidence indicates that HIV entered the human population through 
multiple zoonotic transmissions from the Simian Immunodeficiency Virus (SIV) that 
infects non-human primates [9, 10].  Molecular phylogenetic studies have revealed that 
the likely origin of HIV-1 was an SIV isolate from the chimpanzee (SIVcpz) subspecies 
Pan troglodytes troglodytes that inhabits in the eastern equatorial forests of West 
Central Africa [11, 12]. HIV-2, on the other hand, has evolved from numerous cross-
species transmissions of SIVs of sooty mangabeys (SIVsm) (Cercocebus atys) that 
inhabit in the western parts of Africa (Fig. 3) [13, 14].  
 
Figure 3. Cross-species transmission of HIV and distribution of subtypes and recombinant forms. 
Reprinted with permission from Tebit et al 2011 [15]. 
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High genetic variability, both at the population (inter-host) as well as at the individual 
(intra-host) level is the hallmark of HIV that stems mainly from the inherent infidelity 
of the reverse transcriptase (RT) enzyme. The lack of proofreading mechanisms, 
coupled with an in vivo virus production rate exceeding 10
9
 per day and the persistent 
nature of infection, provides tremendous scope for the generation of viral diversity 
[16]. In addition, the propensity for recombination also contributes to the 
extensive variability of HIV. Intra-subtype genetic diversity differs between 8 and 17%, 
while the inter-subtype genetic diversity usually differs between 17 and 35%, 
depending on the genomic region of HIV-1 or the subtype under study [17].  
Due to this explosive genetic variability, HIV-1 genome has given rise to three distantly 
related groups: M (main), O (outlier) and N (non-M non-O) with unique genetic 
architectures [18, 19]. In 2011, a new group was identified in Cameroon, which is 
termed as putative or P. Interestingly, this forms a distinct cluster that includes the SIV 
sequences from western gorillas (SIVgor; Gorilla gorilla gorilla) [20, 21]. Globally, 
HIV-1 group M dominates the AIDS pandemic and is divided into nine pure subtypes 
[A to D, F to H, J, and K] and several recombinant forms [18]. The recombinants 
between the subtypes are designated as circulating recombinant forms (CRFs) if the 
strains are fully sequenced and found in three or more epidemiologically distinct 
individuals and unique recombinant forms (URFs) if the above criteria are not fulfilled. 
As of February 2013, a total of 58 CRFs have been fully sequenced and numbered 
sequentially from CRF01 to CRF58 (Los Alamos National Laboratory, 
www.hiv.lanl.gov).  
Using the molecular clock dating technique, the time to the most recent common 
ancestor (tMRCA) of the pandemic HIV-1 group M was initially dated back to 1931 
(1915-1941) [22]. After the identification of the oldest HIV-1 viruses ZR59 [23] and 
DRC60 [24] from the Democratic Republic of Congo and inclusion of these strains in 
the analysis, the tMRCA (using Bayesian skyline plot tree prior) was pushed back to 
1908 (1884-1924) [24]. The tMRCA of O and N group was estimated at 1920 (1890–
1940) and 1963 (1948–1977) respectively [25, 26]. The tMRCAs of HIV-2 groups A 
and B were dated back to 1932 (1906-1955) and 1935 (1907- 1961) respectively (Fig. 
3) [26]. 
A recent study on the  global distribution of HIV-1 subtypes over a period between 
2000 and 2007 indicates that subtype C accounts for nearly half of all global infections 
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Figure 5. Distribution of HIV-1 subtypes and recombinant forms (2008). Reproduced with 
permission from Taylor et al 2008 [29], Copyright Massachusetts Medical Society.        
 
[27]. The second most 
common subtype is A, 
which infects nearly 12% 
of individuals followed by 
subtype B with 11% of 
total infections (Fig. 4). 
Among the CRFs, 
CRF01_AE and 
CRF02_AG, accounts for 
5% and 6% respectively. 
Overall, the global distribution of HIV is broadly stable over this period [27, 28]. 
However, the global proportion of all CRFs combined increased by 4.5% [27]. 
Significant disparity has also been observed in terms of spread of HIV-1 subtype 
globally. The first HIV-1 subtype identified was subtype B, which is predominant in 
many resource-rich settings including  North America, western and central Europe 
and Australia, along with other regions like the Caribbean and parts of Latin America, 
while subtype C is predominant in more resource-limited settings like Ethiopia, South 
Africa and India [29] (Fig. 5). Central and western Africa harbors a large diversity of 
subtypes and recombinant forms with CRF02_AG, subtype F, G, H, J, K along with 
other recombinants form. In Asia, specifically China, Myanmar, Thailand, the HIV-1 

















Figure 4. Distribution of major subtypes between 2000 and 2007. 
Data adapted from Hemelaar et al 2011 [27] 
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1.3 HIV-1 SUBTYPE C 
HIV-1 subtype C was first discovered in Ethiopia by Sönnerborg and group in 1988 
[30, 31]. It shares at present 50% of the global infections. [27]. Subtype C 
demonstrates several interesting genotypic and phenotypic properties. Studies have 
shown the existence a third NF-B site in HIV-1 subtype C long terminal repeat (LTR) 
whereas most non-C strains including the commonly studied subtype B viral strains 
have merely two NF-B sites [32]. A more recent study from India, reported the 
presence of an additional 4
th
 NF-B in LTR, and four NF-B strains are expanding and 
replacing the three NF-B sites 
containing subtype C viruses 
[33]. Individuals who are 
infected with viruses harboring 
four NF-B sites had high 
viremia compared to those 
individuals with virus containing 
only three NF-B sites, although 
there was no significant 
difference in their CD4
+
 T-cell 
counts exists [33], which gave 
the conceptual premise that additional NF-κB in the HIV-1 subtype C LTR might 
enhance the viral replication competence by enhancing the infectivity (Fig. 6). 
Another important difference is in neuropathogenetic ability. HIV-associated 
dementia (HAD) is common among untreated HIV-1 subtype B-infected individuals, 
but less common in subtype C infections [34]. It has been postulated that genetic 
differences in viral protein Tat at position 31C residue (termed as C30C31 motif) can 
play an important role in deduced neuropathogenesis by HIV-1. The disruption of the 
C30C31 motif due to the polymorphism, C31S, results in deficient monocyte 
chemotaxis than its subtype B counterpart [35]. A more recent study from HIV-1 
subtype C from Botswana, also showed a significant linear relationship between Tat 
mediated LTR transactivation and patients clinical factors like plasma viral load and 
CD4
+
 T-cell counts [36]. Apart from this, several subtype C specific genetic signature 
residues were reported clinically important reverse transcriptase (RT) and protease 
(PR) region of Pol [37-39]. Significant co-receptor related disparities also have been 
observed in HIV-1 subtype C. In the later stage of disease nearly 50% of the subtype 
Figure 6. Schematic model portraying a novel strategy the 
NF-κB mediated replication competence. Reproduced with 
permission and modification from Bachu et al 2012 [33] 
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B strains are X4-tropic [40], while in subtype C, majority the strains use exclusively 
the CCR5 co-receptor [41]. Details have been described in the later section of the 
thesis.  
Significant disparity also has been observed in the clinical course of HIV-1 infection 
and development of drug resistance with subtype C viruses. Studies have been shown 
that a substantial proportion of HIV-infected adults maintained a high viral set point 
after acute subtype C infection and might be responsible for rapid spread of this viruses 
[42]. However, a more recent study from Africa showed that subtype C and non-C 
subtypes do not differ significantly in terms of their viral set point post sero-conversion 
[43].  Thus the spread of HIV-1 subtype C strains is still inconclusive.  However, there 
are likely that multiple factors including viral and host immuno-genetics as well as 
clinical and geographical disease management strategies can play a crucial role in the 
rapid spread and prevalence of HIV-1 subtype C strains globally [44].  
Another important factor is evolution of drug resistance. HIV-1 subtype C showed a 
distinct drug resistant evolution pathway to accumulate different drug resistance 
associated mutations, which has been described in the later section of the thesis.  
 
1.4 HIV-1 VIROLOGY: STRUCTURE AND GENOME 
HIV is a lentivirus of the Retroviridae family and is transmitted as a single-stranded, 
positive-sense, enveloped RNA virus with 9.5 kb genome (Fig. 7). 
 
Figure 7. Model for mature HIV-1 virus. B. Genetic organization of  HIV-1 structural and functional 
genes. The numbers are designated as HXB2 co-ordinate [Source: HIV Los Alamos Database, 
www.hiv.lanl.gov]  
 
The RNA genome encodes three structural polyproteins (Gag, Pol and Env) and six 
regulatory or accessory proteins (Tat, Rev, Vif, Vpr, Vpu and Nef) flanked by non-
coding long terminal repeat (LTR) at both 5’ and 3’ end [45-48]. The gag gene 
encodes the structural proteins matrix (MA), capsid (CA), and nucleocapsid (NC). 
The pol gene encodes the viral enzymes reverse transcriptase (RT), protease (PR), 
and integrase (IN). The env gene encodes the outer glycoprotein that mediates viral 
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entry of permissive cell types [49]. The regulatory proteins, trans-activator of 
transcription, (Tat) and regulator of expression of virion proteins, (Rev) play 
important roles in activation of viral transcription elongation and induction of nuclear 
export of intron-containing viral RNA respectively. Other accessory protein, virion 
infectivity factor (Vif) suppresses the human host factor, apolipoprotein B mRNA-
editing, enzyme-catalytic, polypeptide-like 3G or F (APOBEC3G/3F) that inhibits 
viral infection, while viral protein R (vpr) is an enhancer of post entry infectivity and 
G2 cell cycle arrest. Viral protein U (Vpu) and Negative factor (Nef) play critical 
roles in CD4/MHC down-regulation. Nef also plays an important role in pathogenic 
determinations [49]. 
1.5 HIV-1 PATHOGENESIS 
The pathogenesis of HIV-1 is complex and multifactorial involving the interplay 
between multiple viral and host factors [50-52]. The direct interaction between the viral 
envelope and its cellular receptor, CD4 along with either C-C chemokine receptor type 
5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4), results in a scenario where 
the virus infects key cells of the adaptive immune response, and hijacks the host 
immune system. Following infection, a variety of intracellular mechanisms involving 
the host immunological factors and viral regulatory and accessory proteins are 
important for the clinical course of disease progression [53]. A significant disparity is 
observed in the disease course of HIV-infected individuals. While, those who succumb 
to AIDS relatively soon after infection are termed as rapid progressors and there are 
others, termed as long-term non-progressors who manage to evade clinical progression 
without therapy even after 20-25 years [54-57]. Even more interesting, a group of 
patients named elite controllers can control the viremia below 50 copies/ml viral load 
without any signs of immunodeficiency [58, 59] . 
The infection and clinical progression of HIV-1 is generally divided into three phases: 
1) Primary or acute infection, 2) Latency and 3) AIDS. The first phase of HIV-1 
infection is termed as primary infections and occurs a few weeks after infection (Fig. 8) 
[60]. In this period, an explosive viral replication leading to high viremia has been 
observed which is termed as “acute phase viremia” and during this period the patient is 
highly infectious. The symptoms are generally non-specific and hence frequently not 
recognized as signs of HIV infection. Following this period, due to the strong host 
immune defense, there is a drop in the amount of viral particles in the blood to a “set 
   9 
point” [61]. The risk of viral transmission between hosts largely depends on the viral 
set point [50]. This phase is termed as latent phase since there are new or only minor 
clinical symptoms and typically varies between 5 to 15 years. The last phase is AIDS 
which is characterized by rapid loss of CD4
+
 T-cells and highly elevated viral load. Due 
to the destruction of the body’s immune mechanism, AIDS-associated opportunistic 
infections and malignancies are manifested during this phase.  
 
 
Figure 8. Natural course of HIV infection without therapy. Reprinted with permission from An and 
Winkler 2010 [62]  
 
1.6 HIV-1 TRANSMISSION 
The probability of  HIV transmission depends on the amount of the infectious virus 
particles present in the body fluid, mainly blood and genital fluid in the index patient 
and the extent of exposure of that body fluid [50]. Also, the susceptibility of the 
exposed individual is also clearly important. Generally, transmission events occurs 
among individuals with a blood viral load >3.5 Log10 copies/ mL [63]. Globally, the 
major route of HIV transmission is via sexual intercourse (heterosexual or homosexual 
exposure), needle sharing among injecting drug users (IDU), unsafe needle use in 
medical practice, contaminated blood products through blood transfusions and mother-
to-child transmission (MTCT) [53].  
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1.7 HIV-1 TRANSMISSION AND SUBTYPE DISTRIBUTION IN INDIA  
The HIV-1 epidemic in India is heterogeneous both in terms of geography and mode of 
infections. Though the major route of transmission is heterosexual [7], the north-eastern 
states in India (mainly 
Manipur and Nagaland), 
have epidemics mostly 
driven by IDUs. Based 
on the national data 
2010-11 [7] unprotected 
sex is the major source of 
spread with 87.4% 
heterosexual transmission 
and 1.3% homosexual 
followed by mother-to-
child (5.4%) (Fig 9). 
Identical to the transmission event, data on molecular epidemiology in India indicates 
an epidemic dominated by HIV-1 subtype C [64-67] with occurrences of recombinant 
forms in some geographic pockets. In the past five years, there are increasing reports of 
recombinant strains in mainly northern and north-eastern India with principally 
CRF02_AG, URF_A1C and URF_BC [68-75]. The combined data from 53 previous 
studies on samples collected between 1991 and 2009 is depicted in Figure 10 [37-39, 
68-70, 74-120]. The southern Indian epidemic is dominated by subtype C with sporadic 
reports of recombinants mainly URF_BC and URF_A1C [71, 104]. On contrary, in 
northern and north-eastern India, though there is dominance of HIV-1 subtype C, a high 
frequency of recombinants mainly URF_BC, URF_A1C, CRF01_AE and CRF02_AG 
are reported. However, the identification of HIV-1 subtypes in India is confounded by 
limitations regarding the representation of geographical regions, selection bias of the 
samples and small sample sizes. On the other hand, accurate virus genotyping and 
recombination identification techniques including the selection of genes are important. 
The studies in India mostly looked into a single gene, which may pose serious 
subtyping bias. On the contrary, selection of appropriate bioinformatics algorithms also 
have a founder effect in the typing of the strains [121, 122]. 
Figure 9. Mode of transmission of HIV, in India (2010-11) 
[Source: NACO Annual Report 2011-12] 
























Figure 10. Molecular epidemiology of HIV-1 subtypes circulating in India (1991-2009). This includes 
data from all reports (n=53) in which the subtyping was determined by sequence analysis. A total of 1900 
sequences of HIV-1 LTR (n=28), gag (n=156), pol (n=928), env (n=258), tat (n=102), vpr (n=8), nef 
(n=48), full length (n=13) and multiple genes (n=359) reported from 14 provinces were included in this 
figure. The subtype mentioned here is as reported by the authors. 
 
 
1.8 CONSEQUENCES OF HIV-1 SUBTYPE DIVERSITY 
Differential appearances of viral subtype through a dynamic genetic evolutionary 
process result in diversified HIV-1 pandemic. The consequential viral diversity has 
implications for possible differential co-receptor evolution to enter into the cells, 
transmission efficiency, rates of disease progression, responses to antiretroviral therapy, 
development of drug resistance, and vaccine development [20, 40, 41, 123-127]. The 
major challenges of the subtype diversity might be on therapeutic and preventive 
management of the disease. Is the therapeutic response subtype dependent? Does the 
evolution of drug resistance differ in different subtypes? The questions remain 
unexplained because of limited number of studies in non-subtype B dominated 
countries. 
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1.8.1 Differential co-receptor tropism 
After the discovery of the CD4 molecule as the major cellular receptor for HIV entry 
[128, 129], the presence of secondary cellular receptors for HIV entry into the host 
has been identified [130, 131]. These co-receptors, particularly the chemokine 
receptors, C-C chemokine receptor type 5 (CCR5) and C-X-C chemokine receptor 
type 4 (CXCR4), have been the subject of extensive research attempting to elucidate 
viral entry mechanism and disease progression. Based on the co-receptor usage, HIV-
1 strains are classified as R5-tropic (those that use CCR5 receptor), X4-tropic (those 
that use CXCR4 receptor) or dual-tropic strains (those that are able to use both the 
receptors) [132-134]. Also the viral population within an individual frequently 
consists of a mixture of such strains [40, 135]. Significant co-receptor related 
inconsistencies have been observed among subtypes, especially in the later stage of 
infection. Studies on subtype B had  shown that in the later stage of disease, nearly 
50% of the subtype B strains are X4-tropic [40]. It has also been shown that subtype 
D viruses are mostly X4- or dual-tropic throughout the course of infection compared 
to subtype A [134, 136-138]. On the contrary, subtype C strains frequently used 
exclusively the CCR5 co-receptor even in later stages of disease [41] and X4-
switches have been reported to be extremely rare in Indian subtype C strains [139].  
1.8.2 Efficiency in transmission 
A growing body of scientific evidences suggests a differential transmission efficiency 
of different HIV-1 subtypes. A study from Tanzania showed a high in utero 
transmission rate of HIV-1 with subtype C compared to subtype A and subtype D or 
both [140]. Also, the study for finding out the reason for rapid spread of HIV-1 subtype 
C globally, is inconclusive. A recent study from southern Africa shows that a 
substantial proportion of HIV-1 subtype C-infected individuals maintain a high viral set 
point, which might have contributed to the high spread of HIV-1 subtype C viruses 
[42].  However, a study by Campbell et al [43]  showed that subtype C and non-C 
subtypes do not differ significantly in terms of their viral set point after sero-
conversion, which contradicts the findings of Novitsky et al [42]. A study conducted in 
Thailand among the IDUs showed an increased probability of transmission of 
CRF01_AE as compared to subtype B [141]. Since, multiple factors including viral and 
host immuno-genetics as well as clinical and geographical disease management 
strategies play a pivotal role in viral spread, it may be difficult to conclude whether the 
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differences in transmission probabilities of different subtypes were due to biologic 
properties associated with subtype only [44, 141]. 
1.8.3 Response to therapy  
The scientific evidence on short term efficacy of antiretroviral therapy from resource-
limited settings where non-B subtypes are prevalent have obtained comparable results 
to studies conducted in resource-rich settings in Europe and America [142, 143]. A 
recent systemic review showed that in sub-Saharan Africa, 67% of the patients 
achieved virological success after 2 years of therapy [143]. A study from Botswana on 
HIV-1 subtype C infected patients, the estimated virological failure are 22.1% and 
30.1% at 3 and 5 years respectively [144]. A study from South Africa where subtype C 
is prevalent, reported that 61% of patients achieved virological suppression at 3 years 
[145]. A study from Burkina Faso reported that 81.8% of the patients remained 
virologically suppressed at 3 years [146]. However, a study from United Kingdom 
showed that viral rebound occurs more frequently in subtype C-infected patients, but 
viral suppression is comparable to those infected with subtype B [147]. The study also 
showed that patients infected with subtype C or subtype A, achieved virological 
suppression more rapidly than those with subtype B infection. However, the baseline 
viral load value is less in subtype C or A infected patients compared to subtype B. A 
recent study showed that a substantial proportion of HIV-1 subtype C-infected 
individuals maintained a high viral set point [42]. In the era of “treatment as 
prevention”, this could make the treatment decisions more challenging. Moreover, the 
response to therapy may be hindered due to the subtype-related variability influencing 
resistance pathways. 
1.8.4 Evolution of Drug Resistance  
A growing body of scientific evidence suggests subtype specific differences in the 
evolution of drug resistance. Though the therapeutic responses are similar, there is 
evidently a probability of genetic metamorphoses among subtypes to yield differential 
patterns of resistance pathways in response to antiretroviral pressure [148-150]. The 
influence of drug resistance mutations on the sensitivity to different antiretroviral drugs 
has been well characterized in subtype B, however, this has not yet been done to the 
same extent for other subtypes due to its presence in resource-limited settings. 
Evaluation of virological and enzymatic data conceptually supports that naturally 
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occurring polymorphisms among different non-B subtypes can 
affect their susceptibility to antiretroviral therapy [148]. The resistance pathway against 
nucleoside reverse transcriptase inhibitors (NRTIs), even in subtype C, differs in 
different geographical locales. In Botswana, subtype C-infected failing patients treated 
with zidovudine (AZT) and didanosine (DDI) developed an atypical thymidine 
analogue mutation (TAM) resistance pathway (67N/70R/215Y), a mixture of TAM-1 
(215Y/41L/210W) and TAM-2 (70R/67N/215F/219Q) pathways  compared to subtype 
B [151]. However this has not been observed in subtype C in India, Malawi or South 
Africa when the patients were treated with same NRTIs [89, 152-154]. Another classic 
example is the development of K65R mutations in subtype C which confers resistance 
to tenofovir (TDF) and all other NRTIs except zidovudine [155-159]. The mechanistic 
view reveals that when subtype C reverse transcriptase (RT) synthesized DNA 
from subtype C RNA templates, favored pausing was seen at the nucleotide position 
responsible for the K65R mutation (AAG-to-AGG) but was not seen when the same 
enzyme used a subtype B RT template [156]. These template factors are assumed to 
increase the probability for the development of K65R mutation subtype C [156] which 
is now being observed in patients failing TDF-based first-line regimens [160] as well as 
in the minor viral population among the patients on cART including zidovudine or 
stavudine [159]. 
Similarly, resistance to non-nucleoside reverses transcriptase inhibitors (NNRTIs) also 
showed subtype dependent mutation patterns. In subtype B, the V106A mutation is 
selected after exposure to nevirapine (NVP) or efavirenz (EFV), while in subtype C and 
CRF01_AE it is V106M [89, 97, 151, 154, 161, 162].   
Another important drug target is the protease region of the HIV-1 pol gene, which 
exhibits more inter-subtype variations compared to RT. Significant subtype-specific 
differences have been observed in this region. Analysis of 56 geographic populations 
identified 11 signature protease mutations at positions 12, 13, 15, 19, 35, 37, 41, 63, 
64, 67 and 93. Of these, mutations in positions 63 and 93 are considered to be weak 
drug resistance mutations in subtype B [163]. A study from India also showed the 
high prevalence of L63P (63.2%) in Indian HIV-1 subtype C sequences from therapy-
naïve patients indicating that L63P is most likely represent the naturally occurring 
polymorphism in subtype C sequences thus resistance-associated mutations in 
subtype B may not necessarily translate to resistance in other subtypes [39].    
   15 
1.8.5 Vaccine development 
The global variability of HIV-1 poses a formidable challenge for development of an 
effective vaccine [164]. A robust molecular epidemiology on HIV-1 subtype 
distribution builds the landmark of any operative large-scale immunization strategy 
[165]. The recent clinical trials in Thailand of ALVAC and AIDSVAX have renewed 
optimism in the possibility of developing an HIV-1 vaccine [166]. However, because of 
diverse subtypes in differential geographic locales, it is still controversial whether a 
single vaccine can protect against all the major subtypes and recombinant forms [165]. 
Due to the vast nature of the HIV-1 epidemic world-wide, it is impossible to conduct a 
single study to type the molecular epidemiology. Therefore, studies in different 
geographic pockets will be helpful for tracking the molecular epidemiology in the 
subtype specific epidemic.  It will help in the designing of region-specific vaccines, 
which will be required to protect populations infected by a specific viral strains 
circulating in discrete geographic areas.  
1.9 ANTIRETROVIRAL THERAPY  
In the early 1990s, HIV-1 specific antiviral drugs were given as monotherapy. The 
treatment of HIV-1 infection was revolutionized in the mid-1990s, as the standard of 
care in HIV management advanced to include the administration of a cocktail of 
antiretroviral agents [167]. This introduction of combination anti-retroviral therapy 
(cART) has led to a dramatic reduction in the mortality and morbidity in HIV 
infection [167]. The six classes of anti-retrovirals that are approved by United States 
Figure 11. Targets of anti-retroviral drugs. Reprinted with permission from Fauci 2003 [1] 
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Food and Drug Administrations (US-FDA) and the European Medicines Agency 
(EMA) as of 2011 are NRTIs, NNRTIs, PIs, fusion inhibitors, integrase inhibitors, 
and entry inhibitor-CCR5 antagonists (Fig. 11)  [156].  
Current drug combinations are effective in stalling HIV replication, often leading to a 
4 log10 copies/mL reduction in plasma viremia [168]. However these drug 
combinations do not eradicate the infection. The cART is usually initiated with three 
drugs (2 NRTIs +1 NNRTI/PI) as first-line drugs. More complex combinations with 
these or other classes are used for second-line or salvage therapy. The US-FDA and 
EMA approved drugs for HIV-1 therapy is depicted in Table 1. 
Table I. Class of antiretroviral drugs use in the HIV-1treatment  
Reverse Transcriptase Inhibitors (RTIs) Protease Inhibitors* Entry Inhibitors 
NRTIs NNRTIs Atazanavir (ATV) 
Fusion Inhibitor 
Enfuvirtide, T-20 Zidovudine (AZT) Rrilpivirine (RPV) 
Darunavir (DRV) 
Amprenvir (APV) 
Lamivudine (3TC) Etravirine (ETR) Fosamprenavir (FPV) 
CCR5-Antagonist 
Maraviroc 
Stavudine (d4T) Delavirdine (DLV)** Indinavir (IDV) 
Emtricitabine (FTC) Efavirenz (EFV) Iopinavir (LPV) 
Abacavir (ABC)  Nevirapine, (NVP) Nelfinavir (NFV) Integrase Inhibitor 
Raltegravir 
Elvitegravir Tenofovir (TDF)  Saquinavir (SQV) 
Didanosine (ddI)  Tipranavir (TPV)  
  Ritonavir (RTV)  
*PIs generally prescribed with boosted RTV, ** Not approved by EMA 
1.9.1 Mechanisms of anti-retroviral drugs 
1.9.1.1 Reverse Transcriptase inhibitors: NRTIs and NNRTIs 
There are two classes of reverse transcriptase inhibitors namely the 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), and non-nucleoside 
reverse transcriptase inhibitors (NNRTIs). NRTIs were the first anti-retroviral drugs 
to be approved by US-FDA and EMA in 1987 [169]. To exert their anti-retroviral 
activity, upon entry NRTIs must first be intra-cellularly phosphorylated by cellular 
kinases to form their active 5’-triphosphate forms [170-173]. NRTIs interfere 
thereafter with the reverse transcriptase activity by competing with the natural 
substrates and once incorporated into the viral DNA, they act as chain terminators 
during RNA-dependent DNA or DNA-dependent DNA synthesis in either (–) or (+) 
strands of the HIV-1 proviral DNA [170, 171]. Tenofovir is the only nucleotide 
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reverse transcriptase inhibitor which contains a phosphate molecule in its structure 
and thus only requires phosphorylation to its diphosphate form for performing its 
antiviral activity [172]. The second class of RTI is NNRTIs which binds directly and 
non-competitively to the enzyme reverse transcriptase [174, 175]. The mechanisms of 
all NNRTIs are similar; they bind to distinct sites on the reverse transcriptase enzyme 
and not to the substrate (dNTP) binding site as the NRTIs. It blocks the DNA 
polymerase activity by altering conformational changes which disrupt the catalytic 
site of the enzyme [176]. The NNRTIs are inactive against HIV-2 viruses [177].  
1.9.1.2 Protease Inhibitors 
A protease inhibitor (PI) is a type of drug that targets the enzyme protease and a classic 
example of structure-based drug design [178]. HIV PR inhibitors specifically bind to 
the active site by imitating the tetrahedral intermediate of its substrate and disables or 
blocks the action of the protease [179]. Currently there are ten PIs approved by the US-
FDA and EMA for clinical use [180]. The first generation PIs are saquinavir, ritonavir, 
indinavir, and nelfinavir. However, the clinical efficacy of the first generation of PIs 
was hindered because of low bioavailability, high pill burden and low genetic barrier to 
resistance. To overcome the issue, second generation of PIs boosted with ritonavir 
(amprenavir, fosamprenavir, lopinavir, atazanavir, tipranavir and darunavir), were 
developed. Boosting increases the plasma level of the PIs and has higher genetic 
barriers to the development of drug resistance mutations. 
1.9.1.3 Entry Inhibitors 
HIV-1 entry inhibitors can be subdivided into distinct classes based on 
disruption/inhibition of distinct targets/steps in the process. There are two classes of 
entry inhibitors approved by US-FDA and EMA; 1) Fusion Inhibitors 
(Enfuvirtide/T20) and 2) CCR5 antagonist (Maraviroc). Enfuvirtide (T20) is a linear 
36–amino acid long peptide homologous to a segment of the HR2 region of HIV-1 
gp41 which binds to the HR1 region of gp41 and blocks the formation of the 6-helix 
bundle necessary for fusion [172]. It is generally used as a salvage therapy on patients 
failed multiple therapies. On the other hand, the CCR5 antagonist, maraviroc, binds 
to hydrophobic pockets within the trans-membrane helices of CCR5 and acts as a 
negative allosteric modulator of the CCR5 receptor. Binding to CCR5 prevents HIV 
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gp120 from access to the co-receptor and thereby prevents the fusion process involving 
gp41 from proceeding further [181, 182]. 
1.9.1.4 Integrase Inhibitors 
The first approved integrase inhibitor (II, INI or InSTI for integrase strand transfer 
inhibitor) is raltegravir, which contains a distinct β diketo acid moiety and has selective 
inhibitory activity against the strand transfer step of integration [183-185]. Recently, a 
second II has been approved, elvitegravir [186]. The integrase enzyme of the HIV-1 
binds to the virally encoded DNA and joins it with the host chromosomal DNA 
followed by cellular repair activities which seals the viral DNA into the chromosome 
[187]. The presence of divalent cations in the catalytic core, a highly conserved region 
of integrase, is a key element of binding, forming covalent bonds with the 
phosphodiester backbone of DNA [187]. Raltegravir works by averting the formation 
of these covalent bonds with host DNA. 
1.10 ROLL OUT OF ANTI-RETROVIRAL THERAPY IN INDIA 
National AIDS Control Organisations (NACO) sponsored by Govt. of India initiated 
free ART services on 1
st
 April 2004 in eight government hospitals located in six high 
prevalence states [188]. Since then, the program has been scaled-up rapidly to 292 (as 
of December 2010) Govt. and other supported health care centres providing free first 
line anti-retroviral therapy  [7].  As of January 2012, a total of 486,173 PLHAs are 
receiving free anti-retroviral therapy [189]. The delivery of care and treatment 
services for PLHAs is provided through a three-tier structure; (i) ART centres, (ii) 
Link ART Centres and (iii) Centres of Excellence (COE). Free second-line ART, 
prioritised for women and children, is available only at 10 COEs, and as of April 
2011, there are nearly 2,000 patients receiving free second line ART [190]. The ART 
centres are generally established in medical colleges based on the prevalence of 
PLHAs in the region and NACO provides support in terms of personnel (doctors, 
nurses, councillors etc), antiretroviral drugs, CD4 testing and drugs required for 
treatment of opportunistic infections. 
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1.10.1 Criteria for ART initiations and regimen in India 
First-line ART is the initial regimen prescribed for an ART naïve patient when the 
patient fulfils national clinical and laboratory criteria to start ART i.e. WHO clinical 
stage I and II, CD4
+




WHO Clinical stage II, CD4
+
-T 
cell count <350 cells/mm
3
 or WHO clinical stage IV. The first line drugs include one 
NNRTI, either nevirapine (NVP) or efavirenz (EFV), in combination with two 
NRTIs; zidovudine (AZT) or stavudine (d4T), and lamivudine (3TC). The alternate 
first-line is to replace AZT or d4T with tenofovir (TDF) due to intolerance to 
AZT/d4T [190]. The second line therapy includes AZT/d4T/TDF with 3TC/FTC 
along with the protease inhibitor atazanavir/ritonavir (ATV/r).       
1.10.2 Therapeutic efficacy 
The data on therapeutic response on first-line therapy in India is limited. A study from a 
southern Indian city (Chennai) with a small number of patients (n=40) using generic 
ART, showed a rapid suppression of HIV-1 viral load and 95% patients achieved viral 
load <400 copies/mL within 6 months of therapy [191]. A study from Bangalore among 
perinatally-infected children, revealed that 85% were virologically suppressed on first-
line ART for >2years [192]. A recent study shows that at twelve months after initiation 
of ART, 64.6% and 75% of the patients in another two clinics (Mumbai and Chennai) 
achieved viral load suppression (<1000 copies/mL) [193].  However, data on long term 
efficacy of the national first-line regimen is lacking.  
1.11 HIV-1 DRUG RESISTANCE 
The development of drug resistance is a critical challenge to the success of the 
antiretroviral therapy. Emergence of drug resistance results in incomplete suppression 
of HIV replication, and is fuelled by inefficient access to viral load monitoring, drug 
resistance testing, adherence to ART and inappropriate drug prescriptions with 
monotherapy mainly, which are major problems in many resource-limited settings.  
The transmission of drug resistant strains may compromise the effectiveness of 
national ART programs, especially in resource-limited settings where only a limited 
number of drugs are available [194].  
Several drug resistance mutations lists have been defined for surveillance of transmitted 
drug resistance mutations (TDRM) and acquired drug resistance mutations, such as 
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French National Agency for AIDS Research drug resistant algorithm 
[http://www.anrs.fr/]; IAS-USA Mutations Associated With Drug Resistance [195]; 
Stanford HIVdb drug resistance interpretation algorithm [http://hivdb.stanford.edu/]; 
Los Alamos National Laboratories HIV Sequence database [www.hiv.lanl.gov] and 
Rega Institute Drug Resistance Interpretation Algorithm 
[http://regaweb.med.kuleuven.be/software/regadb], which all are available to interpret 
drug resistance associated mutations [196]. These mutations lists are mainly based on 
the data available for HIV-1 subtype B. Although comparable patterns have been 
reported on non-subtype B strains [197], a selection of drug- resistance mutations in 
subtype B have been identified as naturally occurring polymorphisms in non-B 
subtypes [198, 199].  Such misinterpretation and subsequent inconsistencies in 
reporting rates of transmitted HIV-1 drug resistance in some of the high HIV-
prevalence areas of the world, have led to reconsideration of the TDRM list to make it 
globally relevant. 
In 2007, a standardized list of 80 RT and PR mutations was assembled by WHO to 
assist population based surveillance of TDRM [200]. The list was updated in 2009 and 
at present, there are 93 mutations in both RT (34 NRTI mutation in 15 positions and 19 
NNRTI in 10 positions) and PR (40 mutations in 18 positions) regions of HIV-1 Pol 
[196] . The International AIDS Society-USA provides drug resistance mutations lists 
which are mainly useful for interpretation of drugs resistance mutations in therapy 
failure patients with acquired drug resistance, and are updated periodically every years 
(current update March 2013) [Appendix-I (RT) and II(Major-PI)] [201].  
1.11.1 Transmitted drug resistance 
A meta-analysis of data collected between time periods <2001, 2001-2003 and >2003 
through 2009, indicated that the prevalence of transmitted drug resistance across 
Europe was 10.9% (95% CI: 10.6-11.3%) while in North America, it is even higher at 
12.9% (95% CI: 12.2-13.7%) [202]. Combined data from studies from resource 
limited settings like Latin America (26 studies), Asia (23 studies) and Africa (47 
studies) where the ART was introduced much later, has reported lower levels of 
TDRMs at 6.3%, 4.2% and 4.7% respectively [202]. However, a recent meta-
regression analysis of the global trends of transmitted drug resistance estimated that 
in East Africa there has been an increase of TDRMs from 0.9% to 7.4% in 8 years 
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after ART roll-out [194]. The TDRMs found most frequently are K103N/S, 
Y181C/I/V and M184V/I.  
1.11.2 Acquired drug resistance 
Previous studies have shown that treatment interruptions, sub-optimal adherence and 
improper dosing can lead to acquired drug resistance [203-205]. Most of the research 
on acquisition of drug resistance mutations, and the impact of DRM on ART have been 
performed primarily for subtype B strains due to its presence in resource-rich settings. 
However, the major challenges remain in resource-limited settings where non-B 
subtypes are present. Different HIV-1 subtypes carry subtype specific genetic signature 
or polymorphisms in its genome that could alter the structure of the viral proteins 
targeted by the drugs [206].  Polymorphisms in reverse transcriptase genes generally do 
not occur in known drug resistance mutation sites of NRTI or NNRTI drugs. In 
contrast, the protease gene is more prone to subtype specific signatures in known drug 
resistance mutation sites of PIs. The subtype B drug resistance mutations in positions 
K20R, M36I and V82I have been observed as naturally occurring polymorphisms in 
non-B subtypes [207]. Recently, our group showed 63%  prevalence of L63P mutation 
in PI naïve Indian subtype C sequences, a mutation that is also selected by PIs in 
subtype B sequences, indicating that this mutation is likely to be a naturally occurring 
polymorphism in Indian C strains [39]. 
Several studies have shown the differential accumulation of NRTIs and NNRTIs 
mutations in different subtypes. There are two well-known pathways to thymidine 
analogues conferring resistance to NRTIs, namely thymidine analogues mutation 
(TAM) pathway 1 and 2. TAM-1 includes mutations M41L, L210W and T215Y; while 
TAM-2 is characterized by mutations D67N, K70R, T215F and K219Q/E [195, 208]. 
In subtype B, the TAM-1 is more common than the TAM-2 pathway while TAM-2 
mutations are more frequent in subtypes C and 01_AE [209]. However in real time, a 
mixture of these mutational pathways can also be observed. Another example is K65R, 
a NRTI mutation which develops rapidly in subtype C viruses when exposed to TDF, 
which might be due to template dependent dislocation mechanisms [158, 160, 210]. 
Similarly, V106M, a NNRTI associated mutation is acquired more frequently in 
NNRTI-exposed subtype C viruses compared to subtype B, where V106A mutation is 
more common [211].  
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1.12 DRUG RESISTANCE STUDIES IN INDIA 
Despite widespread availability of antiretroviral, limited information is available on 
the prevalence of transmitted as well as acquired HIV-1 drug resistance in India. 
Surveillance and monitoring of drug resistance reports are coming only from a 
handful of major cities like Chennai, Pune, Mumbai, Chandigarh and Bangalore. The 
studies in surveillance of transmitted drug resistance among recently diagnosed ART-
naïve individuals in India are limited [101, 103, 105]. However, cross-sectional studies 
on chronically infected HIV-1 positive study populations showed the prevalence of 
TDRMs between 1.6% (Mumbai, 2004) and 39% (Chandigarh, 2008) against first-line 
drug regimens that are widely available in India [89, 92, 94-96, 100]. The NRTI 
mutations are mainly T69D, D67N, M41L, M184V and T215S while the NNRTI 
mutations are K101E, K103N, Y181C, V106M and G190A. A recent combined study 
using primary clinical isolates and secondary database sequences from seven states 
(Tamil Nadu, Andhra Pradesh, Maharashtra, Delhi, Karnataka, Madhya Pradesh and 
Manipur) of India identified a low baseline prevalence of transmitted drug resistance 
below 5% (Neogi et al unpublished data).   
Studies on the evolution of drug resistance are limited. Due to the lack of virological 
monitoring, most of the studies were restricted to a cross-sectional analysis on 
immunologically failure patients. A study from Chennai showed M184V, D67N, 
M41L, K70R and T215Y as major NRTI mutations while K103N, Y181C and G190A 
as major NNRTI mutations [212]. Similar patterns were observed from Bangalore 
[205] and Mumbai [89]. As a consequences of limited access of viral load monitoring, 
most of the time the patients are coming with either immunological or clinical failure. 
In those cases a wide range of cross-resistance even in the newer class of drugs were 
reported. A study from Bangalore reported that in a failing regimen including 
nevirapine or efavirenz, 40% of the subtype C infected Indian patients had at least 
partial resistance to etravirine, a newer class of NNRTI drug [213].  Similar observation 
was reported from Mumbai where the patients were exposed to NVP/EFV for 1 to 8 
years, 45% were resistance to etravirine [214]. 
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2 RATIONALE OF THE STUDY 
HIV-1 translational genomics: exploring the past and present to 
understand the future 
The genetic diversity and multiplicity of HIV is a pivotal factor in HIV vaccinology. 
In order to foretell the future course of HIV-1 disease management strategy in India, 
we need to understand the precedent history of HIV-1. Despite being the third largest 
country with PLHA, studies on basic and translational research on understanding HIV-
1 epidemiology and biology remain inadequate in India. Attempts have been made to 
understand the origin of HIV-1 subtype C in India [215, 216] and the tMRCA of HIV-1 
subtype C in India was dated back to the mid-to late 1970s. Although these studies have 
a strong scientific basis, there is an element of uncertainty in this estimate due to the 
inherent bias of a small sample size, use of information from a secondary database, and 
limited detailing of the geographic origins of samples. Furthermore, tMRCA estimates 
based on a single gene analysis may suffer from a limitation in that the rate of evolution 
of the viral genes may differ significantly due to the variable selection pressure exerted 
by host factors [217]. As a consequence, the actual date of viral introduction may be 
underestimated [218]. 
The continual evaluation of transmitted and acquired drug resistance mutations is the 
back bone of long term therapeutic success and effective disease management. The 
efficacy of an antiretroviral treatment regimen depends on several factors, including 
viral, behavioural and host genetics. The critical one being the evolution of drug 
resistance mutations accumulated over time, both transmitted and acquired. Unlike 
resource-rich countries, drug resistance genotyping at baseline is not part of standard-
of-care management in India. This is mainly because of limited resources, scarcity of 
laboratory infrastructure and trained human resources to perform the test. Thus, drug 
resistance genotyping is restricted to the research arena in India and is currently not 
used for guiding policy on therapeutic strategies.  
Similarly, data on long term virologic outcome of patients using the Indian national 
first-line regimen with two NRTIs and an NNRTI is limited. A previous study with a 
small number of patients using generic antiretroviral therapy identified a rapid 
suppression of HIV-1 viral load [191]. Another study showed that of the 927 patients 
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whose treatment outcome information was available, 71% were alive at the end of two 
years [219]; however, virological data was not available as viral load monitoring was 
not part of standard practice. The data on treatment efficacy beyond two years was not 
examined.  
Therefore, to improve our knowledge for better therapeutic and preventive strategies to 
combat HIV/AIDS in India, this thesis describes the central importance of molecular 
epidemiology in translational genomics of HIV-1 subtype C from origin to therapeutic 
response.  In a systemic approach, we identified the molecular epidemiology of HIV-1 
subtypes circulating in India and described the tMRCA of predominant HIV-1 subtype 
C strains. Next, we examined drug resistance mutations in children, adolescents and 
adults, the role of host factors in evolution of drug resistance, population dynamics of 
viremia and viral co-receptor tropism in perinatal transmission. Finally, we studied 
long-term therapeutic responses on Indian national first-line antiretroviral therapy. This 
thesis thus offers a glimpse into the past and present of HIV-1 molecular epidemiology 
which can be pieced together as a mirror to assist in understanding the future of the 
epidemic for India and the world. 
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3 AIMS AND OBJECTIVES 
The general aim of this thesis is to understand the molecular phylogeny of HIV-1 in 
India with its direct implications on therapeutics and vaccine development. As India is 
poised to provide and scale up free treatment support to the people living with 
HIV/AIDS and initiate sub-unit based vaccine trials using the genes from the HIV-1 
subtype C viruses, my translational research has potentials to link the basic science 
findings with the arena of clinical investigation and public health strategies for effective 
therapeutic management and vaccine developments. 
The specific aims are: 
1. To describe the molecular epidemiology of HIV-1 subtypes in India based on 
samples collected from nationwide clinical cohorts between 2007 and 2011 
and to reconstruct the time to the most recent common ancestor (tMRCA) of 
the predominant HIV-1 subtype C strains. 
2. To identify the clinical significance of human APOBEC mediated drug 
resistance mutation and to explore use of proviral DNA genotyping for drug 
resistance mutation surveillance and monitoring. 
3. To characterise the HIV-1 subtype C infection in Indian children and 
adolescents with perinatal HIV-1 transmission with regard to transmitted drug 
resistance and genotypic co-receptor and the association with clinical, 
virological and host genetic determinants. 
4. To investigate the long term virological outcome among Indian HIV-1 infected 
patients on national first-line therapy, following initial viral suppression and to 




4 MATERIALS AND METHODS 
4.1 STUDY SETTINGS 
The majority of the patients hailed from three states of southern India, Karnataka, 
Tamil Nadu and Andhra Pradesh. For Paper I additional samples were collected from 
another four states Punjab and Haryana in northern India, Manipur in north-eastern 
India, and Madhya Pradesh in central India (Fig. 12). The southern Indian patients 
attended two tertiary care hospitals, St. John’s Medical College and Hospital in 
Bangalore and Krishna Rajendra Hospital in Mysore. The participants from northern 
India were from Post Graduate Institute of Medical Education and Research in 
Chandigarh and those from central India were attending from Ruxmiben Deepchand 
Gardi Medical College, Ujjain. The participants from north-eastern India were from the 
Manipur Network of Positive People (MNP+). A portion of the children and 
adolescents who participated in the study were from Sneha Care Home in Bangalore 
which is a faith-based residential care facility for children infected with HIV who have 
lost one or both parents. The participants from Sneha Care Home routinely obtain 













Figure 12. Study sites for Paper I from where the samples were collected. The dark colour shed 
represents the geographical origin of the study subjects. 
   27 
4.2 STUDY DESIGN AND PATIENT POPULATION 
Among the five papers presented in the thesis, four (I-IV) were cross-sectional studies 
while the final study (V) was a longitudinal cohort with a follow-up of two years. The 
total number of patients involved was 695, and includes 20% children ≤10 years of age 
(136/695), 7% adolescents aged 11-19 years (47/695) and 73% adults (512/695). 
Among them 55% (384/695) were therapy-experienced while the rest were therapy-
naïve. The study design and populations for the respective papers are outlined below. 
Paper I: A single peripheral blood sample was obtained from HIV-1 infected 
seropositive subjects (n= 168) hailing from different regions of India including northern 
(Punjab and Haryana), southern (Karnataka, Tamil Nadu and Andhra Pradesh), north-
eastern (Manipur) and central (Madhya Pradesh) regions between October 2007 and 
November 2011.  
Paper II:  Cross-sectional blood samples were collected from 102 HIV-1 positive 
individuals from southern India between November 2009 and October 2011. A fraction 
of whole blood was kept. Plasma was separated out from the remaining part of the 
samples.  
Paper III: A cross-sectional blood sample was obtained from 105 study subjects 
between March 2007 and October 2011, during a routine follow up visit in the clinic. 
These children were aged between 2 and 16 years and were perinatally infected, ART-
naïve, and with no antenatal exposure to ART.  
Paper IV: The study participants for this study were perinatally-infected children 
(n=139) aged 2-17 years who attended the Pediatric Infectious Disease Clinic, St. 
John’s Medical College and Hospital, Bangalore, India and resided in southern Indian 
states Karnataka, Andhra Pradesh and Tamil Nadu. Cross-sectional blood samples were 
collected between August 2007 and May 2011 from 78 antiretroviral therapy-naive and 
61 ART-experienced children.  
Paper V: The patient populations were derived from a large observational clinical 
cohort of 533 patients from two tertiary care hospitals in southern part of India, which 
adhere to the national therapeutic guidelines [205, 220]. The criteria used for inclusion 
were: (i) Adult HIV-1 infected patients initiated on first-line ART for a minimum 
period of 6 months, and (ii) a viral load <100 copies/ml at the time of entry into the 
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study. The patients were followed up for every 3 months and evaluated for self-reported 
adherence, adherence barriers and other health behaviors. The blood samples were 
collected in every 6 months for a total follow-up period of 2 years beginning in August 
2007.  
Table II. Schedule of events in Paper V. 
 BL MT03 MT06 MT09 MT12 MT15 MT18 MT21 MT24 
CD4 Count X - X - X - X - X 
Viral Load X - X - X - X - X 
DR Genotyping* X - X - X - X - X 
Adherence X X X X X X X X X 
*If viral load >2000 copies/mL 
 
4.3 PATIENTS’ DEMOGRAPHY AND LABORATORY ASSESMENT 
Basic demographics like age, gender, year of HIV-1 sero-diagnosis, treatment details 
for the therapy-experienced patients, were documented during the first study visit. 
Routine CD4
+
T-cells were measured either with FACSCalibur system (BD, USA) (at 
Central laboratory, St. John’s Hospital, Bangalore) or a single platform flow cytometric 
assay (PCA system; Guava Technologies Inc., Hayward, CA, USA at Molecular 
Diagnostics and Genetics, Reliance Life Sciences, Mumbai, India.). Viral load for the 
study purpose, which is not a part of the standard of care, was measured either by 
Abbott m2000rt system (Abbott Molecular Diagnostics, US) or an in-house real time 
polymerase chain reaction with TAQMAN assay (Molecular Diagnostics and Genetics, 
Reliance Life Sciences, Mumbai, India). 
4.4 ADHERENCE MEASUREMENTS 
Adherence during the past month at baseline and past three months (V) was measured 
months during the study visit using a visual analogue scale (VAS) [221]. The VAS is a 
horizontal line marked with numbers between 0 and  100 on which the participant use 
to indicate a point that best corresponds to the percentage of prescribed pills actually 
taken according to his/her self-assessment. Although multiple objective and subjective 
based self-reported adherence measures are available, the VAS has been found to be the 
best predictor of virological failure in this setting [222]. 
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4.5 DEFINITIONS OF TERMS 
Viral rebound: Intermittent viral rebound was defined as a single episode of detectable 
viral load >100 copies/mL. 
Virological failure: Virological failure was defined as two successive viral load values 
>400 copies/mL. 
Perfect Adherence: Perfect adherence was  defined as a combination of two types of 
adherence measurements into one dichotomous variable: Percent of prescribed pills 
taken, assessed with the  Visual Analogue Scale (VAS) and Treatment interruptions, 
defined as having missed medications for more than 48 hours in the past three months. 
To be classified as “perfectly adherent”, the patients had to report 1) taking 100% of 
prescribed doses in the past three months (past one month at baseline) at each study 
visit in which they were present and 2) zero treatment interruptions during the 2-year 
study period.  
4.6 DNA/RNA EXTRACTION  
Genomic DNA was extracted from whole blood using QIAamp Blood DNA kit 
(Qiagen, Germany) while viral RNA was extracted using QIAamp viral RNA kit 
(Qiagen, Germany) and stored for polymerase chain reactions (PCR), reverse 
transcriptase-PCR of viral genes, drug resistance genotyping and co-receptor tropism 
analysis, as described in later section. 
4.7 PCR AND SEQUENCING 
Reverse transcriptase polymerase chain reactions were performed to prepare cDNA 
from plasma viral RNA using random hexamer primer (Promega, USA). HIV-1 p17 
region gag (HXB2 position 790-1190), RT region of pol (HXB2 position 2598-3254) 
and C2V4 region of env (HXB2 position 7050-7550) from cDNA and whole blood 
genomic DNA were amplified by nested polymerase chain reaction (PCR) using 
iNtRON Taq Polymerase (Intron Biotech, South Korea) and the primers listed in Table 






Table III. Primes used for PCR amplification and sequencing.  
Fragment Primer sequence HXB2 Pos Paper 
gag p17  
SJ017F (Outer) 5’-TCTCTCGACGCAGGACTCGGCTTGCTG-3’ 682-708 
I 
SJ017R (Outer) 5’- TAACATTTGCATGGCTGCTTGATGTCC-3’ 1366-1392 
SJ018F (Inner) 5’-CTAGAAGGAGAGAGAGATGGGTGCGAG-3’ 776-800 
SJ018R (Inner) 5’-CTTGTGGGGTGGCTCCTTCTGATAATG-3’ 1310-1336 
pol reverse transcriptase (RT)   
RT04F (Outer) 5’-CCTATTGAAACTGTACCAGT-3’ 2559-2578 
I, II, III, 
V 
RT05R (Outer) 5’-ACTGTCCATTTATCAGGATG-3’ 3252-3271 
RT07F (Inner) 5’-AAGCCAGGAATGGATGGCCCA-3’ 2585-2606 
RT06R (Inner) 5’-CCATTTATCAGGATGGAGTTC-3’ 3246-3266 
env C2V4 region   
IN_ED5 (Outer) 5'-ATGGGATCAAAGCCTAAAGCCATGTG-3’ 6557-6582 
I, IV 
IN_ED12 (Outer) 5'-AGTGCTTCCTGCTGCTCCCAAGAACCCAAG-3’ 7782-7811 
IN_ES7 (Inner) 5'-CTGTTAAATGGCAGTCTAGC-3’ 7002-7021 
IN_ES8 (Inner) 5'-CACTTCTCCAATTGTCCCTCA-3’ 7648-7668 
Note: Inner primers used for sequencing 
 
Table IV: PCR Conditions used for the respective gene fragments. 
Proviral gag p17, pol reverse transcriptase (RT), env C2V4 region Paper 
First round PCR 1 x 95°C: 2 min 
3 x 94°C: 1 min, 55°C: 1 min, 72°C: 3 min, 
32 x 94°C: 1 min, 60°C: 1 min, 72°C: 3 min  
1 x 72°C: 10 min. 
I-II 
Nested PCR 1 x 94°C: 2 min,  
3 x 94°C: 1 min, 55°C: 30 sec,  72°C: 3 min, 
32 x 94°C: 1 min, 60°C: 1 min, 72°C: 1 min 
1 x  72°C: 5 min 
Plasma Viral env C2V4 region  
First round PCR 1 x 94°C: 5min;  
39 x 94°C: 20 sec, 55°C: 30 sec, 72°C: 80 sec;  
1 x 72°C: 7 min 
IV 
Nested PCR 1 x 94°C: 5min;  
39 x 94°C: 20 sec, 50
 
°C: 30 sec, 72
 
°C: 60 sec; 
1 x 72°
 
C: 7 min 
Plasma Viral pol reverse transcriptase (RT) 
First round PCR 1 x 95°C: 3 sec;  
39 x 95°C: 20 sec, 55°C: 30 sec, 72°C: 30 sec;  
II,III, V Nested PCR 1 x 95°C: 3min;  
29 x 95°C: 20 sec, 55°C: 30 sec, 72°C: 30 sec; 
1 x 72°C: 5 min 
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Bidirectional population-based sequencing was performed using the forwards and 
reverse inner primers. The sequences were edited manually in BioEdit version 7.1.3.0 
software. All the laboratory sequences were subjected to rigorous quality control using 
neighbor joining phylogenetic tree constructed using Molecular Evolutionary Genetics 
Analysis software version 5 (MEGA 5) to check for PCR cross-contamination [223]. 
Identical sequences were excluded from the analysis. 
4.8 HIV-1 SUBTYPING (I – V) 
Subtyping of specific gene fragments from clinical strains was initially performed  
using a maximum likelihood (ML) phylogenetic tree constructed with appropriate 
models, using the MEGA 5 software with reference sequences of different subtypes, 
downloaded from HIV-1 Los Alamos Database (LANL, www.hiv.lanl.gov). Gene 
segments clustering with a specific subtype were further used for recombinant 
screening in Recombination Identification program version 3 (RIP 3.0). To confirm 
subtype designation, REGA HIV-1 Subtyping Tool - version 2.0 [224] and SimPlot 
analysis [109] were also used. The mosaic pattern of each URF was confirmed by 
phylogenetic
 
analysis of the recombination fragments. 
4.9 ESTIMATING TIME TO THE MOST RECENT COMMON ANCESTORS 
(TMRCA) (I) 
Full length subtype C available at the Los Alamos database, were selected as reference 
sequences since they covered the env, gag and pol regions investigated in this study. 
The phylogenetic analyses were performed in BEAST v.1.6.2 [225] using the general 
time reversible (GTR) substitution model with inverse gamma distribution for all three 
data sets (the best fitting model for all three data sets according to jModelTest [226]). 
Molecular clock analyses were performed to predict when lineages branch off (split) 
from a common ancestor in the evolutionary tree. As the different HIV-1 genes showed 
different rates of evolution, two relaxed molecular clock models, ‘Relaxed: 
exponential’ and ‘Relaxed: log-normal’ were tested in combination with four different 
coalescent tree priors: constant size, exponential growth, logistic growth and Bayesian 
skyline. The resulting log-files were analyzed in Tracer v.1.6.2 [225]. Bayes Factor 
analysis showed that the relaxed log-normal clock with Bayesian Skyline was the most 
appropriate model for all three genes. Tip dates (year of sampling for each sequence) 
together with a previous estimate of the age of subtype C in the year 1952 [217] were 
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used for calibration of the molecular clock (the prior was set to Normal distribution, 
59±6 years since the last year of sampling, 2011), and rates of evolution were 
automatically calculated from these data. The analyses were run for 100 million 
generations with sampling every 10,000 generation, and the sampled trees were 
annotated using TreeAnnotator v1.6.2 and visualized in FigTree v1.3.1 
(http://tree.bio.ed.ac.uk/software/figtree/).  
4.10 DRUG RESISTANCE (II, III AND V)  
The transmitted drug resistance was interpreted using World Health Organization 
(WHO) recommendations for surveillance of drug resistance mutations updated in 2009 
(SDRM_2009) which includes 93 mutations in the 53 RT and 40 PR region of HIV-1 
Pol [196]. To further increase the accuracy of this analyses, certain mutations included 
in the SDRM_2009 which displayed characteristics of likely polymorphisms (defined 
as those mutations which are normally present at a frequency of ≥0.5% in therapy-naïve 
patients, and at a frequency of <0.5% among those failing therapy [196]) were 
eliminated. The acquired drug resistance mutations were interpreted using International 
AIDS Society-USA update  2011 which includes 19 NRTI mutations in 16 positions, 
and 34 NNRTI mutations in 16 positions between amino acid residues 17 to 235 of RT 
region of pol [195].  
4.11 CCR532 GENOTYPING (IV) 
CCR532 genotyping was performed by PCR with subsequent gel electrophoresis as 
described previously [227]. PCR amplicons of either 262 bp (CCR5 wildtype) or 230 
bp length (CCR5Δ32 deletion) were visualized in a 5% ethidium bromide-stained 
agarose gel. 
4.12 GENOTYPIC TROPISM TESTING: SELECTION OF PREDICTION 
TOOL FOR SUBTYPE C (IV) 
A training data set of 465 HIV-1 subtype C V3 loop sequences with known phenotypic 
tropism results were compiled from previously published literature [228-231] and 
LANL HIV sequence database. These sequences were subjected to genotypic tropism 
testing using the different prediction tools for the selection of tools for subtype C 
viruses Table V. 
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Table V. Performance of genotypic tools in predicting X4-tropism in HIV-1 subtype C 
sequences with known phenotypes. 
  
  Phenotypic Concordance Sensitivity Specificity 




   
Geno2Pheno2.5% X4 57 3 94.4 71.3 99.2 
R5 23 382    
Geno2Pheno5% X4 67 7 95.7 83.8 98.2 
R5 13 378    
Geno2Pheno10% X4 69 14 94.6 86.3 96.4 
R5 11 371    
Geno2Pheno15% X4 69 18 93.8 86.3 95.3 
R5 11 367    
Geno2Pheno20% X4 71 41 89.3 88.8 89.4 
R5 9 344    
C-PSSM X4 68 21 92.9 85 94.6 
R5 12 364    
ds(Kernel) X4 62 3 95.5 77.5 99.2 
R5 18 382    
11/25 rule X4 56 3 94.2 70 99.2 
R5 24 382    
11/24/25 rule X4 59 3 94.8 73.8 99.2 
R5 21 382    
Net Charge > 6 X4 61 20 91.6 76.3 94.8 
R5 19 365    
  
Though all the genotypic tools showed a good performance in detecting X4 tropism, a 
better sensitivity (86.3%) and specificity (96.4%) was obtained by Geno2pheno[co-
receptor] with 10% false positive rate (FPR). Thus, Geno2pheno with 10% FPR was 
used to determine the genotypic tropism testing which was also recommended by 
European guidelines for HIV-1 tropism testing [232, 233]. Minor populations with all 
probable combinations of V3 sequences were also included. The tropism interpretation 
was as follows: the sample was considered “X4-tropic”, if all sequences from that 
patient showed FPR ≤10%; or “R5-tropic”, if all the sequences from the patient showed 
FPR >10%. Samples which contained sequences with differing FPRs that were both 
≤10% and >10% were classified as “R5/X4-tropic” samples.  
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4.13 OTHER BIOINFORMATICS ANALYSIS 
4.13.1 Intra-population divergence (II)  
The intra-population divergence (genetic distance of each of the study 
sequences to the Indian consensus C sequence) was calculated in MEGA 5 
software. 
4.13.2 Estimation of G-to-A substitutions (II) 
To estimate G-to-A substitutions, proviral DNA sequences were aligned 
against the consensus Indian subtype C sequence [38]. The hA3G/F mediated 
GG-to-AG and GA-to-AA scores, for each sequence were calculated as 
described previously [234, 235]. The consolidated hA3G/F mediated G-to-A 
hypermutation score: [(Number of GG-to-AG or GA-to-AA 
substitutions/number of GG or GA in Indian consensus sequence)/(Total 
number of mutations/Sequence length)]. G-to-A preferences were calculated 
as described [234]. 
4.13.3 Identification of hypermutated sequences (II)   
Hypermut 2.0 software was used to determine hA3G/F mediated 
hypermutated sequences [236]. To further increase the confidence in the 
analysis, cluster analysis of preference for G-to-A substitutions relative to 
consolidated hA3G/F score and sequence analysis of 21 hA3G and 20 hA3F 
target sites in the 17-235 aa of the RT region identified by APOBEC3G-
mediated defectives (A3GD) indices [237] were also used. Hypermutations 
were labeled into a dichotomous variable if identified by one of the methods 
mentioned.  Mutations were designated as lethal if there was a stop codon in 
the open reading frame (ORF).  
4.14 STATISTICAL ANALYSIS 
Differences between groups on continuous variables were examined by independent 
sample t-test or Mann–Whitney U-test, while categorical variables were analyzed via 
frequencies and cross-tabulations, with χ2 tests or Fisher’s exact test to assess the 
significance of the associations. A Spearman rank correlation (rs) was used for analysis 
of potential correlation between continuous variables. Multivariate logistic regression 
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was used to find the significant predictors of continuous variables. P value <0.05 was 
considered as significant. 
4.15 ETHICAL CONSIDERATIONS 
All studies were approved by the institutional ethical review board, St. John’s Medical 
College Hospital, Bangalore, India (IERB/1/655/09, IERB/1/725/2010, 
IERB/1/621/2011(Ref 67/2002), IERB/1/74/08, IERB/1/332/06), PGIMER, 
Chandigarh (MED/2005/1159), National Institute of Immunology, New Delhi 
(IBSC/AKS/2007/22),  RD Gardi Medical College, Ujjain  (M/10/1533), MNP+, 
Imphal (MOU MNP+ dated 29/12/2010) and Committee for Human Research at 
University of California, San Francisco, USA (UCSF-IRB#10-03994; Ref#034080). 
Written informed consent was obtained from all adults and caregivers of children 
prior to recruitment of the children, and a verbal assent was obtained from children > 




5 RESULTS AND DISCUSSION 
The work presented in this thesis is an investigation of the translational genomics of 
HIV-1 subtypes circulating in India. This is one of the most comprehensive and 
detailed studies performed so far in the country. The study comprises data from a large 
population hailing from a wide range of geographical locales which are analyzed by 
sophisticated bioinformatics methods with the purpose of expanding the knowledge 
about the HIV-1 epidemiology in India.  
Paper I presents a comprehensive HIV-1 molecular epidemiology study pertaining to 
India. A total of 168 samples collected between 2007 and 2011 from four distant 
geographical regions of India were used to type the molecular epidemiology. A robust 
HIV-1 subtyping was done using two or three genes, gag, pol, and env by several 
methods. As expected, subtype C was found to be the dominant HIV-1 subtype in 
India. However, for the first time, a high prevalence (10%) of unique recombinant 
forms (BC and A1C) was observed when two or three genes were used instead of one 
gene (p<0.01; p=0.02, respectively). Of the recombinant strains, 6.0% (10/168) were 
identified as recombinants of subtypes B and C, whereas 4.2% (7/168) were 
recombinants of A1 and C. The nearest non-C sequence identified for the subtype B 
segments in the BC recombinant strains was most likely derived from China and 
Thailand while the A1 segment in A1C originated from eastern Africa (Kenya, Uganda 
and Tanzania).  
Similarly, the rest of the papers (II to V) also confirmed the predominance of subtype 
C with more than 98% frequency. A novel unique recombinant forms CH (URF_CH) 
was also identified based on analysis of the RT region of the pol gene (III).  
5.1 ORIGIN OF INDIAN HIV-1 SUBTYPE C 
The tMRCA of Indian HIV-1 subtype C was estimated using three viral genes (I). The 
gag gene analysis estimated the Indian HIV-1 subtype C tMRCA to 1967 [95% CI: 
1957-1975] while the env-analysis provided an estimated tMRCA in 1974 [95% CI: 
1968-1978]. The pol-gene analysis was considered to provide the most reliable 
estimate, 1971 (95% CI: 1965-1976) (Fig. 13).  
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Figure 13. tMRCA of HIV-1 subtype C reported from different regions. The tMRCA of Indian subtype 
C identified in this study are shown in red. Posterior probability plots showing the tMRCA estimates of 
Indian HIV-1 subtype C (Inset): The posterior probability density plots for the three genes (env, pol 
and gag) point to a tMRCA for Indian HIV-1 subtype C from 36.9 (env), 40.5 (pol) and 44.3 (gag) 
years ago, with an overall mean for the combined graph at 40.6 years ago before 2011, that is in 1970.4 
(95% CI: 1960.3–1978.1).  
Our study also indicated that the Indian HIV-1 subtype C epidemic originated from a 
single or few genetically related African lineages, which since then has largely evolved 
independently as analysis of all the three genes (gag, pol and env) showed a large 
monophyletic clade of only Indian subtype C strains segregating from the African 
lineages. However, it was not possible to determine from which country the first 
introduction took place, as the main Indian clades in the pol tree were equidistant to 
all strains in the neighbouring clade. The pol phylogenetic tree also identified a small 
clade mainly consisting of the strains from western, central and north-eastern regions 
of the country, indicating a strong movement of strains among these regions. The 
effective population size in the country has been broadly stable since the 1990s as 
observed in the Bayesian skyline plot. The data corresponds well with the HIV-1 
estimates in India, which indicates a stable or reverse HIV prevalence between 2002 
and 2009 [7]. 
 
 38 
5.2 HUMAN APOBEC3G HYPERMUTATION AND DRUG RESISTANCE 
In Paper II, we aimed to characterize the nature of APOBEC mediated hypermutations in 
the RT region of the pol gene in population of Indian HIV-1 infected patients, and the 
consequences in therapeutic management. The evidence from this study suggests that 
APOBEC3G lethal-hypermutation was associated with the use of treatment in Indian 
patients who failed ART and had subtype C strains. Among the therapy-experienced 
patients 22% (7/32) had lethal hypermutation in the proviral compartment but not in the 
plasma viral compartment. Though drug resistance mutations were present in the 
hypermutated proviral compartment, all strains had a stop codon in their ORF. Therefore, it 
is unlikely that such viral variants will mature and expand in vivo which is supported by the 














Figure 14. Distribution of drug resistance mutations A. NRTI mutations and B. NNRTI mutations in 
plasma viral RNA and proviral genomic DNA 
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A high level (94.6%; 3/56) of concordance in drug resistance was observed in therapy-
naïve individuals but not in experienced individuals (43.8%; 14/32). DRMs were found 
in 84.4% (27/32) of the patients failing ART. Important differences were found 
between the plasma RNA and the proviral DNA compartments. Among the DRMs, few 
patients had M184V (18.75%; 6/32) and T215Y/F (9.4%; 3/32) mutations in plasma 
only, while M41L and K65R were observed in one patient each in provirus only (Fig. 
14). Additional NRTI mutations were observed in 25% (8/32) of each in proviral and 
plasma viral sequences while additional NNRTI mutations were found mainly in 
plasma (31.2%; 10/32) and to a lesser extent in proviral DNA (12.5%; 4/32).  
5.3 LIMITED TRANSMITTED DRUG RESISTANCE IN INDIA 
A low level of transmitted drug resistance was observed in children and adolescents 
(III). Using the SDRM_2009 list [196] for drug resistance survillance, we found that 
among the 105 ART-naïve children, 3.8% (4/105) had transmitted NRTI drug 
resistance mutations (L74I, T69D, T215S and K219Q) and 4.8% (5/105) had NNRTI 
drug resistance mutations [K103N (n=2), K101E (n=2), Y181C (n=1)]. Furthermore, 
we analyzed 606 RT sequences obtained from treatment-experienced patients from 
Indian subtype C patients [downloaded from the Los Alamos database (n=102); 
literature survey (n=446) and unpublished from lab (n=58)], which revealed that T215S 
was not present in any of the sequences while L74I mutation was present in 0.3% 
(2/606). Therefore, we excluded the likely polymorphisms L74I and T215S, and the 
overall prevalence of transmitted drug resistance in this population was found to be 
5.7% (6/105). We also used the IAS-USA 2011 list [195] for TDRM interpretation, and 
a slightly differing result was obtained. The NRTI resistance prevalence was 0.9% 
(1/105; K219Q) and NNRTI resistance was 5.7% [6/105; K103N (n=2), K101E (n=2), 
Y181C (n=1), F227C (n=1)]. The likely polymorphism F227C that confers “minor” 
resistance to rilpivirine, a drug that is still unavailable in India, was however excluded 
and the resulting resistance was the same as with the first method. Recent studies have 
also observed differences in prevalence of TDRM within the same cohort with 
individuals infected with CRF01_AE, when differing tools such as SDRM 2009 and 
IAS-USA 2009 are used [238]. Therefore, it is of high importance that the 
interpretation of prevalence of TDRM in population-based surveillance specifically 
non-B subtypes should be used with caution to avoid reporting falsely elevated TDR 
prevalence in the population.  
 40 
Similarly in the adult population, transmitted drug resistance mutations were observed 
in both compartments in only one patient giving the prevalence of transmitted drug 
resistance as 1.8% (E138K, 1/56) (II). 
5.4 HIGH VIREMIA IN SUBTYPE C INFECTED ADOLECENTS 
The study presented in Paper III, aimed to understand the viral dynamics in perinatal 
transmission at the population level in therapy-naïve children and adolescents of age 
between 2 to 16 years. One of the most significant findings was that a substantial 
proportion (54%; 21/39) of adolescents with subtype C infection presenting with high 





 A low level of transmitted drug resistance in children 
unexposed to antenatal antiretroviral drugs was observed. 
The inconsistent clinical parameters of high viral load and high CD4
+
T-cell count co-
existed in over half the adolescents studied. It is plausible that untreated adolescents 
with high viremia and drug resistance mutations may also play a role in fuelling the 
HIV epidemic. Our study also supports the idea that early initiation of ART while 
emphasizing good adherence may be important both from an individual angle to halt 
disease progression as well as from a public health perspective to attain maximum 
population-level reduction in HIV-1 transmission. 
5.5 CO-RECEPTOR TRANSITION FROM R5- TO X4-TROPISM IN 
SUBTYPE C INFECTIONS WITH LONGER DURATION 
In Paper IV, we aimed to study the predicted co-receptor tropism among the 
perinatally-infected children (n=72) aged between 2 and 17 years. Among children 
with subtype C strains (n = 71), 81.7% 
(58/71) were identified as R5-tropic 
strains with median FPR of 68.1% (range: 
10.5–99.2) and 9.9% (7 of 71) were 
identified as X4-tropic with median FPR 
of 3.15% (range: 0.10–9.70). The 
presence of both R5-tropic and X4-tropic 
sequences were found in 8.5% (6 of 71) 
(Fig. 15). 
Figure 15. Distribution of R5-, X4- and 
R5/X4-tropic strains in the pediatric cohort.  
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Our data for the first time indicated that the likelihood of co-receptor transition from 
R5 to X4 tropism in subtype C increases with the duration of HIV infection. At 
univariate analysis the length of HIV-1 infection, CD4
+
-T cell counts and inter-
population genetic divergence of subtype C were the potential factors associated with 
co-receptor switch from R5- to X4-tropic in perinatally infected patients. However, in 
multivariate logistic regression, adjusting for other parameters such as gender, ART-
naive status, CD4
+
 T-cell count, log viral load, and viral divergence, we found that 
the length of infection was the single independent factor associated with co-receptor 
transition. It was also observed that the therapy-naïve children had 3.3-fold higher 
risk of having X4-tropic or R5/X4-tropic virus compared to therapy-experienced 
children although statistical significance were not obtained due to the small sample 
size of the therapy-experienced group. The evidence from our study also suggests that 
the co-receptor transitions from R5 to X4-tropic is not as uncommon in HIV-1 
subtype C as previously thought [41]. It generally occurs with longer duration of 
infection and greater disease progression and can have therapeutic implications for 
the future, specifically for the use of CCR5-antagonists like maraviroc in clinical 
practice. 
5.6 GOOD LONG TERM THERAPEUTIC RESPONSE TO NATIONAL 
FIRST LINE ANTIRETROVIRAL THERAPY 
The Paper V is the first study in the country to assess the long term virological 
outcome among Indian HIV-1 infected patients on Indian national first-line therapy, 
following initial viral suppression below the detection level (<100 copies/mL). In this 
longitudinal cohort study, we assessed the factors associated with virological rebound, 
its consequences, and emergence of drug resistance mutations in a cohort of 323 
patients. Our results indicate a good overall long-term response to first-line therapy 
reflecting an overall success of the standardized Indian national program for individuals 
with HIV infection. Among the patients, 75.2% (243/323) were able to maintain ≥95% 
adherence throughout the study and 47.4% (153/323) were able to maintain perfect 
adherence (100% adherence by VAS and no treatment interruptions lasting more than 
48 hrs) during the same time. The median duration of viral suppression was 44 months 
(IQR 36-54) and 15.8% (51/323) of patients showed intermittent viral rebound without 
failure during this study period. Viral failure was observed in only 2.8% (9/323) of 
patients. Among the patients who did not achieve perfect adherence, 24.1% (41/170) 
experienced viral rebound or failure, which is nearly twice the proportion of perfectly 
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adherent patients with viral rebound or failure (12.4%; 19/153, p<0.01).Drug resistance 
mutations were identified in 9 of the 16 patients who had single episode of viral 
rebound (Fig 16).  As expected [205, 213], M184V was the major NRTI drug 
resistance mutation seen, along with G190A/M, K103N, Y181C and V108I. Among 
these 16 patients, seven had successfully controlled viremia in their subsequent 6-
month follow-up study visit without any change of therapy. The most interesting 
finding is that, among the seven patients with controlled viremia, three had multiple 
major NRTI/NNRTI mutations [M184V+G190A; M184V+K103N; M184V+Y181C) 
during their viral rebound, but later during subsequent visits became suppressed 
without change of therapy. It is also important to note that they had maintained >95% 
adherence both before and after the viral rebound as well as maintained good 
immunological status with CD4
+ 
T-cell counts in the normal range. Studies on subtype 
C virus from South Africa showed that despite the presence of NNTRI mutations such 
as K103N, V106M and G190A, a fraction of patients were successfully re-suppressed 
on the same regimen [239, 240]. Studies from Sweden, Belgium and South Africa also 
showed that despite the presence of NRTI mutations such as M184V, viral re-
suppression occurred in a fraction of patients with virological rebound [239-242]. 
Figure 16. Distribution of drug resistance mutations among the virologically 
rebound/failure patients during their first viremia >2000 copies/mL. 
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6 CONCLUSIONS  
This thesis provides an account of HIV-1 subtypes circulating in India, including the 
origin, the molecular phylogeny, and characterizations of the predominant HIV-1 
subtype C in relation to drug resistance mutations, role of host factor in evolution of 
drug resistance, viremia, co-receptor switch and the long-term therapeutic response on 
Indian national first-line antiretroviral therapy. This study described the central 
importance of molecular epidemiology in translational genomics of HIV-1 from origin 
to therapeutic response with an aim to improve the available therapeutic and preventive 
strategies for combating HIV/AIDS. The following conclusions can be drawn: 
1. HIV-1 subtype C was confirmed as the dominating strain in India. However, 
after using comprehensive subtyping methodology, a significant increase in 
recombinant strains was observed. This indicates an evolving heterogeneous 
viral epidemic in India. This could pose serious challenges to the development 
of an effective vaccine that would be applicable in the whole country (I). 
2. The Indian HIV-1 subtype C epidemic originated nearly four decades ago 
from a single or few genetically related African lineages, and since then 
largely evolved independently and formed a separate monophyletic clade 
segregating from the larger subtype C clade (I). 
3. The molecular data using Bayesian Skyline plot showed a stable epidemic of 
HIV-1 subtype C which corresponded with the National AIDS Control 
Program (NACP) launched by Govt. of India in the 1990s (I). 
4. Our study (II) identified that APOBEC3G mediated lethal-hypermutations were 
associated with treatment failure among Indian patients. Though drug resistance 
mutations like M184I and/or M230I, were present in the hypermutated proviral 
compartment, all strains had a stop codon in its open reading frame; therefore, it 
is unlikely that the drug resistance-containing progeny will expand in vivo.  
5. An implication of this study (II) is the possibility of using proviral DNA as an 
alternative to plasma viral RNA for surveillance of transmitted drug resistance. 
As the proviral genotyping technique utilizes whole blood, it does not require 
cold chain transport, which facilitates studies in resource-limited settings, 
especially from rural and remote part of the country where logistic challenges 
remain. 
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6. The presence of key mutations like K65R and M41L in the proviral DNA 
compartment in therapy-failure patients may be of importance for the selection 
of future ART regimen (II). 
7. The low level of transmitted drug resistance in children and adults is reassuring. 
Our study also suggests that interpretation of TDRM prevalence in population-
based surveillance with non-B subtypes should be used with caution. Inclusion 
of likely polymorphisms might falsely elevate the TDR prevalence in the 
population (III). 
8. More than half the adolescents living with HIV-1subtype C included in the 
study had inconsistent clinical parameters of high viral load and high CD4
+
 T-
cell counts. Therefore, early initiation of ART while emphasizing good 
adherence may be considered in this population in order to attain maximum 
population-level reductions in HIV-1 transmission (III). 
9. The likelihood of the high proportion of predicted X4-tropic strains in the 
older children advocate that co-receptor transition can occur with longer 
duration of infection and greater disease progression which might have 
therapeutic implications for the use of CCR5-antagonist Maraviroc in future 
(IV). 
10. Our study showed a good overall response with a median of four years, to a 
regimen containing two NRTI and one NNRTI drugs (as in the Indian national 
first-line antiretroviral therapy regimen), indicating the overall success of the 
Indian ART program. Less than perfect adherence i.e. 100% adherence and no 
treatment interruption for more than 48 hours increases the risk for treatment 
failure and subsequent drug resistance development (V). 
11. A subset of patients with major drug resistance mutations like M184V, K103N 
and Y181C had suppressed viremia without change in therapy as they had 
optimal adherence profile throughout the study period. Our study therefore 
provides support for the conceptual evidence that viral load measurement can 
act as an indicator for adherence. Early identification of viremia followed by 
targeted special adherence counseling to these patients may limit the 
unnecessary switch to the second-line of therapy, especially in resource-limited 
settings, where limited drug options are available (V).  
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7 RECOMMENDATIONS FOR FUTURE STUDIES 
This research has thrown up many questions which invite further investigation. A 
further comprehensive biological characterization of the Indian HIV-1 subtype C needs 
to be performed to understand this specific viral strain. The following recommendations 
can be made for further studies: 
1. India initiated its vaccine development program as early as 1998. However, the 
depth of sampling (the proportion of available sequences compared to total 
number of estimated infections) is still very low (~0.03%). The resulting 
diversified epidemiology indicated by an increase in recombinant strains, may 
pose a serious challenge to the development of an effective vaccine that would 
be applicable in the country. Ongoing countrywide molecular surveillance of 
HIV-1 subtypes is likely to contribute towards a better understanding of the 
epidemiology in this region and to guide efficient disease intervention 
strategies. 
2. The role of APOBEC3G in the evolution of drug resistance needs to be 
validated by further studies of the clinical consequences through analysis of a 
large number of patients and by appropriate in vitro cell culture models to gain 
the mechanistic view of the APOBEC-mediated drug resistance mutations.   
3. High viremia in non-immunosuppressed adolescents may also play a role in 
fuelling the HIV epidemic. The question remains, will this group of adolescents 
with extended high viremia experience imminent rapid disease progression as 
has been seen in adult studies? What will be the therapeutic response among 
such patients with high viremia? Therefore, longitudinal analyses to understand 
the disease progression, therapeutic response and immune re-establishment 
need to be investigated.  
4. Though the current scientific literature supports good correlation between 
population sequencing and interpretation of viral tropism using the Geno2Pheno 
system with phenotypic tests, in vitro studies using an appropriate cell culture 
model needs to be performed to validate the findings. Also, the role of minor 
viral populations in the evolution of co-receptor transition needs to be 
investigated using more sensitive techniques like next generation sequencing.    
5. The low level of transmitted drug resistance in children and adults is reassuring 
but should not advocate complacency. As there is an increase in the therapeutic 
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coverage through free national ART program, regular surveillance is necessary 
to understand the evolution of transmitted drug resistance mutations in the 
population. 
6. An appropriate drug resistance mutation algorithm for subtype C needs to be 
established for surveillance of transmitted drug resistance. Also future research 
should investigate the role of drug resistance and treatment outcome with HIV-
1 subtype C viruses to identify the optimal time of switching failing patients to 
appropriate second-line regimens. 
7. Finally, as Indian subtype C showed distinct genotypic characteristics compared 
to South African subtype C, considerably more work are to be done to 
determine the phenotypic and biological characteristics of these strains, in order 
to guide efficient disease intervention and management strategies.  
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10 APPENDICES 
Appendix I:  Mutations in the reverse transcriptase gene concomitant with resistance 
to reverse transcriptase inhibitors, NRTI and NNRTI (adapted from International 
AIDS society-USA list of DRM: March 2013 Update) 
 
Drugs Resistance Mutations 
Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (NRTIs) 
Abacavir (ABC) K65R, L74V, Y115F, M184V 
Didanosine (ddI) K65R, L74V 
Emtricitabine (FTC) K65R, M184V/I 
Lamivudine (3TC) K65R, M184V/I 
Stavudine (d4T) M41L, K65R, D67N, K70R, L210W, T215Y/F, K219Q/E 
Tenofovir (TDF) K65R, K70E 
Zidovudine (AZT) M41L, D67N, K70R, L210W, T215Y/F, K219Q/E 
69 insertion complex M41L, A62V, 69ins, K70R, L210W, T215Y/F, K219Q/E 
151 complex A62V, V75I, F77L, F116Y, Q151M 
TAM-1 T215Y, M41L, L210W 
TAM-2 K70R, D67N, T215F, K219Q 
Non-nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs) 
Efavirenz (EFV) 
L100I, K101P, K103N/S, V106M, V108I, Y181C/I, Y188L, G190S/A, 
P225H, M230L 
Nevirapine (NVP) 
L100I, K101P, K103N/S, V106M/A, V108I, Y181C/I, Y188C/L/H, 
G190A, M230L 
Etravirine (ETR) 
V90I, A98G, L100I, K101E/H/P, V106I, E138A/G/K/Q, V179D/F/T, 
Y181C/I/V, G190S/A, M230L 
Rilpivirine (RPV) 
K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, 
F227C, M230I/L 
 
Abbreviations: TAM- Thymidine Analogue Mutation 
Amino acid abbreviations: A-Alanine; C-Cysteine; D-Aspartate; E-Glutamate; F-Phenylalanine; G-
lycine; H-Histidine; I-Isoleucine; K-Lysine; L-Leucine; M-Methionine; N-Asparagine; P-Proline; Q-










Appendix II: Major mutations in the protease gene concomitant with resistance to 
protease inhibitors (adapted from International AIDS society-USA list 2013 and 
Stanford Drug Resistance Database, http://hivdb.stanford.edu). 
 
Drugs Resistance Mutations 
Atazanavir/r (ATV/r) 
V32I, M46I/L, I47V, G48V/M, I50L, I54V/T/A/M, V82A/T/F/S, I84V, 
N88S, L90M 
Darunavir/r (DRV/r) V32I, I47V/A, I50V, I54L/M, L76V, V82F, I84V, 
Fosamprenavir/r (FPV/r) 
V32I, M46I/L, I47V/A, I50V, I54V/T/A/L/M, L76V, V82A/T/F/S, I84V, 
L90M 
Indinavir/r (IDV/r) 
V32I, M46I/L, I47V/A, I54V/T/A, L76V, V82A/T/F/S, I84V, N88S, 
L90M 
Lopinavir/r (LPV/r) 
V32I, M46I/L, I47V/A, G48V/M, I50V, I54V/T/A/L/M, L76V,  
V82A/T/F/S , I84V, L90M 
Nelfinavir/r (NFV/r) 
D30N, M46I/L, I47V/A, G48V/M, I54V/T/A/L/M, V82A/T/F/S , I84V, 
N88D/S, L90M 
Saquinavir/r (SQV/r) G48V/M, I54V/T/A/M, V82A/T, I84V, N88S, L90M 
Tipranavir/r (TPV/r) V32I, M46I/L, I47V/A, I54V/T/A/M, V82L/T, I84V, 
 
 
 
 
 
 
 
 
